Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

Autor: Montserrat Marques-Pamies, Joan Gil, Elena Valassi, Marta Hernández, Betina Biagetti, Olga Giménez-Palop, Silvia Martínez, Cristina Carrato, Laura Pons, Rocío Villar-Taibo, Marta Araujo-Castro, Concepción Blanco, Inmaculada Simón, Andreu Simó-Servat, Gemma Xifra, Federico Vázquez, Isabel Pavón, Rogelio García-Centeno, Roxana Zavala, Felicia Alexandra Hanzu, Mireia Mora, Anna Aulinas, Nuria Vilarrasa, Soledad Librizzi, María Calatayud, Paz de Miguel, Cristina Alvarez-Escola, Antonio Picó, Miguel Sampedro, Isabel Salinas, Carmen Fajardo-Montañana, Rosa Cámara, Ignacio Bernabéu, Mireia Jordà, Susan M. Webb, Mónica Marazuela, Manel Puig-Domingo
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Frontiers in Endocrinology, Vol 14 (2023)
Druh dokumentu: article
ISSN: 1664-2392
DOI: 10.3389/fendo.2023.1269787
Popis: IntroductionWe previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .MethodsA total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs’ response. Those patients whose IGF1 decreased to
Databáze: Directory of Open Access Journals